As of the latest Form 4 filed Jul 1, 2026.
What Protara Therapeutics Inc insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 22 most recent filings for TARA.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-07-01 | 2026-06-30 | Shefferman Jesse CEO and President | GGift | −5.00K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-07-01 | 2026-06-30 | Shefferman Jesse, CEO and President | GGift | −4.00K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-07-01 | 2026-06-30 | Shefferman Jesse, CEO and President | GGift | −7.00K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-07-01 | 2026-06-30 | Shefferman Jesse, CEO and President | GGift | −14.0K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-07-01 | 2026-06-29 | Shefferman Jesse, CEO and President | SSale | −216K | $4.09 | $882K | No | Form 4 ↗ |
| 2026-07-01 | 2026-06-29 | Shefferman Jesse, CEO and President | MExercise | +216K | $1.91 | $412K | No | Form 4 ↗ |
| 2026-06-03 | 2026-06-02 | CONKLING WILLIAM Chief Commercial Officer | FTax | −6.01K | $4.34 | $26.1K | No | Form 4 ↗ |
| 2026-04-09 | 2026-04-08 | Zummo Jacqueline Chief R&D Officer | SSale | −1.13K | $5.40 | $6.12K | No | Form 4 ↗ |
| 2026-01-27 | 2026-01-26 | Shefferman Jesse CEO and President | FTax | −8.73K | $6.67 | $58.2K | No | Form 4 ↗ |
| 2026-01-27 | 2026-01-26 | Zummo Jacqueline Chf Scientific Operations Off | FTax | −3.72K | $6.67 | $24.8K | No | Form 4 ↗ |
| 2026-01-27 | 2026-01-26 | Fry Hannah VP, Controller | FTax | −1.46K | $6.67 | $9.72K | No | Form 4 ↗ |
| 2026-01-27 | 2026-01-26 | Fabbio Patrick Chief Financial Officer | FTax | −3.26K | $6.67 | $21.8K | No | Form 4 ↗ |
| 2026-01-22 | 2026-01-20 | Shefferman Jesse CEO and President | FTax | −16.3K | $5.60 | $91.4K | No | Form 4 ↗ |
| 2026-01-22 | 2026-01-20 | Fabbio Patrick Chief Financial Officer | FTax | −3.06K | $5.60 | $17.2K | No | Form 4 ↗ |
| 2026-01-22 | 2026-01-20 | Zummo Jacqueline Chf Scientific Operations Off | FTax | −6.58K | $5.60 | $36.8K | No | Form 4 ↗ |
| 2026-01-22 | 2026-01-20 | Fry Hannah VP, Controller | FTax | −2.13K | $5.60 | $11.9K | No | Form 4 ↗ |
| 2026-01-21 | 2026-01-16 | CONKLING WILLIAM Chief Commercial Officer | AAward | +26.0K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-01-21 | 2026-01-16 | Fabbio Patrick Chief Financial Officer | AAward | +28.0K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-01-21 | 2026-01-16 | Fry Hannah VP, Controller | AAward | +9.50K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-01-21 | 2026-01-16 | Nicacio Leonardo Viana Chief Medical Officer | AAward | +26.0K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-01-21 | 2026-01-16 | Shefferman Jesse CEO and President | AAward | +87.0K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-01-21 | 2026-01-16 | Zummo Jacqueline Chf Scientific Operations Off | AAward | +30.0K | $0.00 | $0.00 | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also TARA’s full analysis or the market-wide insider trading feed. The tabs above jump to TARA’s other SEC data.
Source: SEC Form 4 filings for TARA, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.